Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

TABLE 7.2 Times Associated with Vaccine Use and Benefits

Pathogen (Target Population)

Type of Vaccine

Time to Licensure (years)

Time After Licensure to Adoption (years)

Total Time to Steady State of Vaccine Use (years)

Delay of Vaccination Benefits (years)

Total Time to SteadyState Yield of Benefits (years)

Dengue virus

(Infants and children in endemic areas; travelers to endemic areas)

Attenuated live vector virus containing gene for broadly cross-reacting protective antigen

10

2

12

5

17

Escherichia coli

(enterotoxigenic)

(Infants < 6 months)

A combination of purified colonization factor antigens and possibly other antigens

10

2

12

1

13

Genetically engineered attenuated strains

10

2

12

1

13

Hemophilus influenzae type b

(Infants)

Conjugated polysaccharide

3

5

8

2

10

Hepatitis A virus

(Susceptibles of all ages; routine for preschool children)

Attenuated live virus

4

5

9

2

11

Polypeptide recombinant vaccine produced in yeast

5

5

10

2

12

Hepatitis B virus

(Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous With other vaccinations, at earliest possible age)

Polypeptide produced by recombinant DNA technology

1

2

3

30

33

Japanese encephalitis virus

(Children in epidemic and endemic areas; foreign visitors to epidemic regions)

Inactivated virus produced in cell culture

7

2.5

9.5

7

16.5



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement